ConcertAI is set to showcase its latest advancements in multimodal and real-world data management at the American Society of Clinical Oncology (ASCO) annual meeting. This year, the spotlight will be on Cara AI and the TeraRecon Oncology Suite, two innovative tools designed to enhance research capabilities and streamline complex clinical workflows.
Cara AI stands out for its ability to integrate radiological imaging studies, digital pathology, and both structured and unstructured real-world data (RWD). This platform offers an open AI framework that allows researchers to incorporate and manage AI algorithms from various sources for image and data processing. Key features of Cara AI include advanced AI orchestrations using large language models (LLMs), natural language processing (NLP), and predictive AI. It also supports oncology- and hematology-specific LLMs, and operates on data derived from electronic medical records (EMRs), molecular radiological imaging, and digital pathology. This platform is touted as the first of its kind, optimized for predictive and generative AI.
According to Jeff Elton, CEO of ConcertAI, the focus over the past two years has been on developing, validating, and deploying AI models that utilize multi-modal data. These models are crucial for making causal inferences and eliminating confounders, which are essential for accurate interpretations and predictions in clinical trials and patient care.
Also featured at ASCO 2024 will be the TeraRecon Oncology Suite, an integrated set of AI-powered diagnostic tools aimed at detecting lung cancer, identifying prostate cancer, and characterizing brain tumors. This suite is designed to enhance early detection and provide precise diagnoses, helping manage cancer patients throughout their care journey. The tools offer oncology-centric solutions that support and guide care delivery, integrating smoothly into existing clinical workflows.
The TeraRecon Oncology Suite’s capabilities are further enhanced by its seamless integration into the ConcertAI network, which was established in 2021. This integration aims to create a unified network and AI-enabled workflows for both clinical research and decision support applications, emphasizing the suite’s role in improving patient outcomes through innovative AI-driven solutions.
In summary, ConcertAI’s presentations at ASCO 2024 will highlight significant strides in AI-driven research tools and diagnostic capabilities. Cara AI and the TeraRecon Oncology Suite are poised to advance the field of oncology by providing robust, integrated solutions that support comprehensive data analysis and patient care management.